Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about AngioDynamics, Inc.
AngioDynamics, Inc. News
AngioDynamics, Inc. Quantitative Score

About AngioDynamics, Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
AngioDynamics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
AngioDynamics, Inc. Financials
Table Compare
Compare ANGO metrics with: | |||
---|---|---|---|
Earnings & Growth | ANGO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ANGO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ANGO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ANGO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
AngioDynamics, Inc. Income
AngioDynamics, Inc. Balance Sheet
AngioDynamics, Inc. Cash Flow
AngioDynamics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Sell |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Neutral |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
AngioDynamics, Inc. Executives
Name | Role |
---|---|
Mr. James C. Clemmer | Chief Executive Officer, President & Director |
Mr. Stephen A. Trowbridge | Executive Vice President & Chief Financial Officer |
Ms. Laura Piccinini | Senior Vice President & GM of Cardiovascular and International |
Mr. Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain |
Mr. Chad T. Campbell | Senior Vice President & GM of Oncology and Interventional Devices |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. James C. Clemmer | Chief Executive Officer, President & Director | Male | 1964 | 1.61M |
Mr. Stephen A. Trowbridge | Executive Vice President & Chief Financial Officer | Male | 1974 | 764.27K |
Ms. Laura Piccinini | Senior Vice President & GM of Cardiovascular and International | Female | 1969 | 706.93K |
Mr. Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Male | 1969 | 625.37K |
Mr. Chad T. Campbell | Senior Vice President & GM of Oncology and Interventional Devices | Male | 1971 | 592.76K |
AngioDynamics, Inc. Insider Trades
Date | 16 Jan |
Name | Nighan Warren JR |
Role | SVP Quality and Regulatory |
Transaction | Disposed |
Type | S-Sale |
Shares | 4060 |
Date | 2 Dec |
Name | Weiss Lawrence T |
Role | SVP, Chief Legal Officer |
Transaction | Acquired |
Type | A-Award |
Shares | 52697 |
Date | 2 Dec |
Name | Weiss Lawrence T |
Role | SVP, Chief Legal Officer |
Transaction | Acquired |
Type | A-Award |
Shares | 103650 |
Date | 2 Dec |
Name | Weiss Lawrence T |
Role | |
Transaction | Disposed |
Type | |
Shares | 0 |
Date | 7 Oct |
Name | Nighan Warren JR |
Role | SVP Quality and Regulatory |
Transaction | Acquired |
Type | P-Purchase |
Shares | 768 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
16 Jan | Nighan Warren JR | SVP Quality and Regulatory | Disposed | S-Sale | 4060 |
2 Dec | Weiss Lawrence T | SVP, Chief Legal Officer | Acquired | A-Award | 52697 |
2 Dec | Weiss Lawrence T | SVP, Chief Legal Officer | Acquired | A-Award | 103650 |
2 Dec | Weiss Lawrence T | Disposed | 0 | ||
7 Oct | Nighan Warren JR | SVP Quality and Regulatory | Acquired | P-Purchase | 768 |